Patrick Alexander Ott

Patrick Alexander Ott's AcademicInfluence.com Rankings

Philosophy

#9086

World Rank

#12591

Historical Rank

Logic

#6080

World Rank

#7562

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Patrick Alexander Ott Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Patrick Alexander Ott's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. (2015) (2383)
An immunogenic personal neoantigen vaccine for patients with melanoma (2017) (1820)
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy (2018) (1272)
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. (2016) (975)
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial (2018) (754)
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. (2016) (730)
CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients (2013) (595)
Towards personalized, tumour-specific, therapeutic vaccines for cancer (2017) (577)
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. (2016) (513)
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. (2019) (481)
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. (2016) (455)
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. (2013) (432)
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer (2018) (381)
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy (2016) (381)
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, phase 1/2 trial (2016) (376)
Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. (2017) (368)
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. (2013) (346)
Loss of PTEN Is Associated with Resistance to Anti‐PD‐1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma (2017) (345)
PD-1 Inhibitor–Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course (2016) (341)
Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients (2017) (322)
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. (2017) (305)
Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. (2018) (294)
Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. (2017) (293)
Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. (2019) (289)
Combination immunotherapy: a road map (2017) (287)
Advances in the development of personalized neoantigen-based therapeutic cancer vaccines (2021) (273)
Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies (2016) (272)
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer (2020) (231)
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study (2018) (227)
Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer (2018) (224)
The efficacy of anti‐PD‐1 agents in acral and mucosal melanoma (2016) (204)
Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study (2014) (197)
Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data (2015) (196)
A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab (2015) (188)
Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab (2015) (187)
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial (2016) (186)
Clinical activity of ipilimumab for metastatic uveal melanoma (2013) (176)
Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma (2021) (168)
Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery (2013) (167)
HLA-Binding Properties of Tumor Neoepitopes in Humans (2014) (165)
Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028. (2019) (165)
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. (2020) (146)
525 Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028 (2015) (146)
Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study. (2015) (144)
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors. (2016) (142)
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic Small-Cell Lung Cancer: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. (2019) (141)
Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma (2021) (140)
Ipilimumab for patients with advanced mucosal melanoma. (2013) (140)
PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients. (2018) (136)
Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis (2017) (134)
Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. (2017) (125)
Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma (2013) (121)
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal (2017) (113)
Vemurafenib and radiation therapy in melanoma brain metastases (2013) (111)
A Phase II Trial of Sorafenib in Metastatic Melanoma with Tissue Correlates (2010) (104)
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal (2017) (102)
Mucosal melanomas: a case-based review of the literature. (2010) (101)
Inhibition of both BRAF and MEK in BRAFV600E mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties (2013) (101)
PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma (2015) (100)
Abstract S5-07: Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028 (2016) (99)
Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028. (2015) (99)
Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy (2017) (95)
Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions (2017) (95)
The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors. (2019) (91)
Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition (2019) (90)
CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC). (2016) (88)
Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032. (2017) (87)
Pembrolizumab for the treatment of programmed death–ligand 1‒positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE‐028 study (2020) (85)
Comparison of cytokine ELISpot assay formats for the detection of islet antigen autoreactive T cells. Report of the third immunology of diabetes society T-cell workshop. (2003) (83)
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021. (2021) (79)
NCCN Guidelines® insights: Melanoma, version 3.2016: Featured updates to the NCCN Guidelines (2016) (79)
The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature. (2020) (76)
Talimogene Laherparepvec for the Treatment of Advanced Melanoma (2016) (73)
Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma (2015) (72)
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma. (2014) (72)
Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study. (2017) (71)
Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study. (2016) (70)
Immune response in melanoma: an in-depth analysis of the primary tumor and corresponding sentinel lymph node (2012) (65)
Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management (2018) (64)
PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. (2015) (63)
A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. (2020) (57)
T Cells Recognize Multiple GAD65 and Proinsulin Epitopes in Human Type 1 Diabetes, Suggesting Determinant Spreading (2004) (56)
Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment. (2011) (54)
Pembrolizumab in patients with advanced cervical squamous cell cancer: Preliminary results from the phase Ib KEYNOTE-028 study. (2016) (53)
427OPembrolizumab for patients with PD-L1–positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study (2017) (52)
Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas (2015) (51)
Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non‒small-cell lung cancer. (2016) (51)
Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation. (2017) (50)
Pembrolizumab for patients with advanced prostate adenocarcinoma: Preliminary results from the KEYNOTE-028 study (2016) (49)
A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens. (2018) (47)
CD28 costimulation enhances the sensitivity of the ELISPOT assay for detection of antigen-specific memory effector CD4 and CD8 cell populations in human diseases. (2004) (47)
Directing Traffic: How to Effectively Drive T Cells into Tumors. (2020) (47)
NCCN Guidelines Insights: Melanoma, Version 3.2016. (2016) (45)
Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032 (2015) (45)
Cytokine detection by ELISPOT: relevance for immunological studies in type 1 diabetes (2002) (45)
Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study. (2016) (44)
Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. (2015) (43)
Pembrolizumab in patients (pts) with PD-L1–positive (PD-L1+) advanced ovarian cancer: Updated analysis of KEYNOTE-028. (2017) (43)
Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies (2018) (42)
A phase 2 study of glembatumumab vedotin, an antibody‐drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma (2019) (42)
The cytokine signature of MOG-specific CD4 cells in the EAE of C57BL/6 mice (2005) (42)
Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial (2012) (42)
Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study. (2015) (38)
Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma (2016) (37)
Clinical Features of Acquired Resistance to Anti–PD-1 Therapy in Advanced Melanoma (2017) (36)
Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma Patients (2017) (36)
Impact of MAPK Pathway Activation in BRAFV600 Melanoma on T Cell and Dendritic Cell Function (2013) (35)
Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer (2021) (33)
IL-2 absorption affects IFN-gamma and IL-5, but not IL-4 producing memory T cells in double color cytokine ELISPOT assays. (2005) (33)
New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy (2014) (32)
Islet-cell antigen-reactive T cells show different expansion rates and Th1/Th2 differentiation in type 1 diabetic patients and healthy controls. (2005) (32)
Abstract CT073: Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer (SCLC): Results from the KEYNOTE-028 and KEYNOTE-158 studies (2019) (30)
The Biology and Clinical Development of MEK Inhibitors for Cancer (2014) (30)
A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti–PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors. (2014) (29)
Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma (2019) (29)
An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines. (2019) (29)
Pembrolizumab in advanced endometrial cancer: Preliminary results from the phase Ib KEYNOTE-028 study. (2016) (28)
CD4+CD25+ regulatory T cells control the progression from periinsulitis to destructive insulitis in murine autoimmune diabetes. (2005) (28)
Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors. (2019) (26)
Increased in vivo frequency of IA-2 peptide-reactive IFNgamma+/IL-4- T cells in type 1 diabetic subjects. (2004) (26)
Pembrolizumab for previously treated advanced anal squamous cell carcinoma: Pooled results from the KEYNOTE-028 and KEYNOTE-158 studies. (2020) (26)
MA09.05 Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial (2017) (25)
Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma (2018) (25)
Phase I/II, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) as monotherapy or combined with ipilimumab in advanced or metastatic solid tumors. (2014) (24)
OA05.01 Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer: Updated Survival Results from KEYNOTE-028 (2017) (24)
Landscape of helper and regulatory antitumour CD4+ T cells in melanoma (2022) (23)
Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CheckMate 069). (2016) (23)
Novel therapeutics for melanoma (2009) (23)
Vaccines and melanoma. (2014) (23)
Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor‐induced colitis (2020) (23)
A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broad de novo anti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder cancer. (2018) (22)
Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma (2017) (22)
NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019. (2020) (21)
Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1 (2020) (21)
Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial (2020) (20)
Phase II Trial of Dacarbazine and Thalidomide for the Treatment of Metastatic Melanoma (2009) (20)
Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma (2018) (20)
Transformation of Old Concepts for a New Era of Cancer Immunotherapy: Cytokine Therapy and Cancer Vaccines as Combination Partners of PD1/PD-L1 Inhibitors (2018) (20)
Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series (2017) (20)
Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma (2015) (19)
Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, DUR) + tremelimumab (TRE) in patients with advanced solid tumors. (2017) (19)
Pembrolizumab in patients with MSI-H advanced endometrial cancer from the KEYNOTE-158 study (2019) (19)
Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis. (2020) (18)
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results from the KEYNOTE-028 Study (2018) (18)
500 Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028 (2015) (18)
Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series (2017) (18)
Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study. (2022) (17)
Checkmate 032: Nivolumab (N) alone or in combination with ipilimumab (I) for the treatment of recurrent small cell lung cancer (SCLC). (2016) (17)
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis (2022) (16)
Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors (2021) (16)
Abstract CT301: A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors (2020) (16)
Mutational load (ML) and T-cell-inflamed microenvironment as predictors of response to pembrolizumab. (2017) (16)
Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. (2019) (16)
Cost of cardiac care in the three years after coronary catheterization in a contained care system: critical determinants and implications. (1998) (16)
PD-1 inhibitors in endometrial cancer (2017) (15)
The secretory IFN-gamma response of single CD4 memory cells after activation on different antigen presenting cell types. (2007) (15)
Hair depigmentation as an indicator of durable response to CTLA-4 therapy. (2010) (15)
Automated Flow Synthesis of Tumor Neoantigen Peptides for Personalized Immunotherapy (2020) (14)
Safety and clinical activity of first-line durvalumab in advanced NSCLC: Updated results from a Phase 1/2 study. (2017) (14)
A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL). (2013) (14)
Optimized Liquid and Gas Phase Fractionation Increases HLA-Peptidome Coverage for Primary Cell and Tissue Samples (2021) (14)
Kinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advanced cancer: synergistic or antagonistic? (2013) (14)
Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer (2019) (14)
CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study (2021) (14)
Cutaneous Melanoma , Version 2 . 2019 (2019) (13)
T-cell inflamed phenotype gene expression signatures to predict clinical benefit from pembrolizumab across multiple tumor types. (2016) (13)
Cancer Immunotherapy Principles and Practice (2018) (13)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts (2016) (12)
A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence (2015) (12)
Abstract 2673: Association of PD-L1 combined positive score and immune gene signatures with efficacy of nivolumab (NIVO) ± ipilimumab (IPI) in patients with metastatic gastroesophageal cancer (mGEC) (2019) (12)
Abstract CT002: Initial report of overall survival rates from a randomized phase II trial evaluating the combination of nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma (MEL) (2016) (12)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
Surgical approach to primary cutaneous melanoma. (2011) (11)
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study (2021) (11)
The B7-H1/PD-1 pathway in cancers associated with infections and inflammation: opportunities for therapeutic intervention. (2012) (11)
A Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) in Patients with Metastatic Melanoma (2010) (11)
Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma (2019) (10)
Efficacy and safety of programmed death receptor-1 (PD-1) blockade in metastatic uveal melanoma (UM). (2016) (10)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
Personal Neoantigen Vaccines for the Treatment of Cancer (2021) (9)
Clinical activity and safety of pegylated human IL-10 (AM0010) in combination with anti-PD1. (2016) (9)
Nivolumab monotherapy in metastatic urothelial carcinoma: Longer-term efficacy and safety results from the CheckMate 032 study. (2018) (9)
Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge (2016) (9)
Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma (2016) (9)
A phase II study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma. (2017) (8)
Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders (2021) (8)
Abstract 942: The personalized vaccine, NEO-PV-01 with anti-PD1, induces neoantigen-specific de novo immune responses in patients with advanced metastatic melanoma: Association with clinical outcomes (2019) (8)
H05Phase 1/2 study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032 (2015) (7)
674PNivolumab (NIVO) in patients (pts) with advanced (adv) chemotherapy-refractory (CT-Rx) esophagogastric (EG) cancer according to microsatellite instability (MSI) status: checkmate 032 (2017) (7)
A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma (2016) (7)
Effect of dexamethasone in glioblastoma (GBM) patients on systemic and intratumoral T-cell responses induced by personalized neoantigen-targeting vaccine. (2018) (6)
A phase I study to evaluate the safety and tolerability of MEDI4736, an anti- programmed cell death-ligand-1 (PD-L1) antibody, in combination with tremelimumab in patients with advanced solid tumors. (2015) (6)
Response and oligoclonal resistance to pembrolizumab in uterine leiomyosarcoma: Genomic, neoantigen, and immunohistochemical evaluation. (2016) (6)
A first-in-human dose escalation study of PEGylated recombinant human IL-10 (AM0010) in advanced solid tumors. (2015) (6)
Abstract CT125: A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broadde novoanti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder cancer (2018) (6)
Targeted modified IL-2 (NHS-IL2, MSB0010445) combined with stereotactic body radiation in advanced melanoma patients after progression on ipilimumab: Assessment of safety, clinical, and biologic activity in a phase 2a study. (2014) (6)
Intralesional Cancer Immunotherapies. (2019) (6)
Phase I/II study of arginine deiminase (ADI-PEG 20) in patients with advanced malignant melanoma (MM). (2016) (6)
Anti-tumor activity of PEGylated human IL-10 (AM0010) in patients with pancreatic or colorectal cancer. (2016) (6)
Combined BRAF and MEK inhibition in BRAF(V600E) mutant melanoma: a synergistic and potentially safe combination partner with immunotherapy. (2015) (6)
Two-year overall survival rates from a randomised phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma (2017) (6)
Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care (2017) (6)
3098 Nivolumab (NIVO) monotherapy or in combination with ipilimumab (IPI) for treatment of recurrent small cell lung cancer (SCLC) (2015) (6)
84PDRelationship of PD-L1 and a T-cell inflamed gene expression profile (GEP) to clinical response in a multicohort trial of solid tumors (KEYNOTE [KN]028) (2017) (6)
Challenges in neoantigen-directed therapeutics. (2022) (5)
Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study. (2022) (5)
Immunotherapy: Immune-modified response criteria — an iterative learning process? (2018) (5)
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors (2022) (5)
Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated With Anti-PD-1 Therapy (2018) (5)
Implications of mRNA-based SARS-CoV-2 vaccination for cancer patients (2021) (5)
Long-term Overall Survival and Predictors in Anti–PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study (2021) (4)
Association of vitamin D intake with decreased risk of immune checkpoint inhibitor-induced colitis. (2020) (4)
Genomic biomarkers in relation to PD-1 checkpoint blockade response. (2018) (4)
General Principles of Immune-Related Toxicities (2019) (4)
Treatment for advanced melanoma: new drugs, new opportunities, new challenges. (2013) (4)
Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial (2021) (4)
Enrollment in Clinical Trials Correlates with Improved Survival in Metastatic Melanoma (2012) (4)
Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service (2020) (4)
KEYNOTE - D36: personalized immunotherapy with a neoepitope vaccine, EVX-01 and pembrolizumab in advanced melanoma. (2022) (4)
Cancer vaccines (2022) (3)
Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint Inhibitors. (2021) (3)
Anti-tumor activity of PEGylated human IL-10 (AM0010) in renal cancer alone and in combination with anti-PD1 (2016) (3)
Nivolumab monotherapy in patients with advanced gastric or gastroesophageal junction (GEJ) cancer and 2 or more prior treatment regimens: Sub-analysis of the CheckMate 032 study. (2017) (3)
Abstract 5631: Personal neoantigen-targeting vaccination generates neoepitope-specific T cell responses in tumors of patients with glioblastoma (2018) (3)
Pembrolizumab for vulvar squamous cell carcinoma: results from the phase 2 KEYNOTE-158 study (2021) (3)
Preliminary results of PROCLAIM-CX-072: The first-in-human, dose-finding trial of PD-L1 probody therapeutic CX-072 as monotherapy in patients (pts) with advanced solid tumors. (2018) (3)
Clinical activity of anti-programmed death-1 (PD-1) agents in acral and mucosal melanoma. (2016) (3)
Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti–PD-1 Era (2022) (3)
A phase Ib study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO). (2020) (3)
Combination anti-PD-1 and ipilimumab (ipi) therapy in patients with advanced melanoma and pre-existing autoimmune disorders (AD). (2020) (3)
A comparison of skin cancer screening and treatment costs at a Massachusetts cancer center, 2008 versus 2013 (2018) (2)
Analysis of patients (pts) with in-transit metastases treated with nivolumab (NIVO) or ipilimumab (IPI) in CheckMate 238. (2021) (2)
Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab (2017) (2)
Immune-related tumor response dynamics in melanoma patients (pts) treated with pembrolizumab: Identifying markers for clinical outcome and treatment decisions. (2017) (2)
Survival of advanced melanoma patients with normal LDH treated with oblimersen, temozolomide, and nab-paclitaxel. (2009) (2)
Phase I/II study of Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma (2013) (2)
A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO). (2)
Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials. (2018) (2)
Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma. (2012) (2)
Nivolumab monotherapy in metastatic urothelial cancer (mUC): Updated efficacy by subgroups and safety results from the CheckMate 032 study (2016) (2)
Abstract A010: Personalized neoantigen-targeting vaccines for high-risk melanoma generate epitope spreading (2019) (2)
Pharmacodynamic (PD) changes in tumors and peripheral blood T cell receptor (TCR) repertoire in a phase I study combining OX40 (PF-04518600) and 4-1BB (utomilumab) agonistic monoclonal antibodies (mAbs). (2018) (2)
[Immediate results of combined treatment for soft tissue sarcomas including intraoperative radiation therapy]. (2013) (2)
Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade (2021) (2)
1142PDSafety, pharmacokinetics (PK) and pharmacodynamics (PD) data from a phase I dose-escalation study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600) in combination with utomilumab, a 4-1BB agonistic mAb (2017) (2)
Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab. (2017) (2)
Use of Vemurafenib, a BRAF Inhibitor Along With Radiation Therapy in Melanoma Brain Metastasis (2012) (2)
Phase I/II study of the TLR3 agonist poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 vg in patients with melanoma. (2014) (2)
PD-1 inhibition - trouble for subsequent TIL therapy in patients with melanoma? (2022) (2)
481 Impact of COVID-19 on Cancer Patients Receiving Immune Checkpoint Inhibitors (2020) (2)
Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated With Anti-PD-1 Therapy (2019) (2)
Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. (2022) (2)
How physicians can help create useful clinical practice guidelines. (1999) (1)
T Cell Modulation: Anti-PD-1 Antibodies for the Treatment of Cancer (2015) (1)
1207TiPAn open-label, Phase IB study of NEO-PV-01 + Adjuvant with Nivolumab in Patients with Melanoma, Non-Small Cell Lung Carcinoma, or Transitional Cell Carcinoma of the Bladder (2017) (1)
Abstract P6-18-31: PROCLAIM-CX-072: Monotherapy for advanced triple negative breast cancer with skin metastases in a phase 1-2 trial of the PD-L1 probody therapeutic CX-072 (2019) (1)
Abstract 4989: Toxicity profile of contemporaneous PD-1 inhibitor immunotherapy and radiotherapy (2016) (1)
Detecting neoepitope-specific intra-tumoral T cell responses in a glioblastoma patient treated with personal neoantigen vaccine (2018) (1)
Retrospective review of outcomes following radiotherapy for oligoprogressive disease on immune checkpoint blockade. (2022) (1)
Principles of Combination Immunotherapies (2021) (1)
Pathology of durable stable disease in melanoma patients treated with ipilimumab, nivolumab, or ipilimumab, and nivolumab combination therapy. (2021) (1)
PD-1 and PD-L1 Inhibition in the Treatment of Advanced Melanoma (2014) (1)
Abraxane, temozolomide, and oblimersen (The ATG Trial): A final report of toxicity and clinical efficacy in metastatic melanoma patients with normal lactate dehydrogenase (LDH). (2011) (1)
T-cell receptory AV repertoire analysis of peripheral blood lymphocytes in antibody positive first degree relatives and type 1 diabetic patients (1996) (1)
655 Landscape of helper and regulatory CD4+ T cells in melanoma (2021) (1)
PD-1 inhibitor-related pneumonitis in advanced cancer patients. (2016) (1)
648 Cytokine changes during immune-related adverse events and steroid treatment in melanoma patients receiving immune checkpoint inhibitors (2020) (1)
Optimized liquid and gas phase fractionation increase HLA-peptidome coverage for primary cell and tissue samples (2021) (1)
An open-label, phase Ib study of NEO-PV-01 + adjuvant with nivolumab in patients with melanoma, non-small cell lung carcinoma, or transitional cell carcinoma of the bladder. (2017) (1)
Abstract CT166: A Phase I/II, open-label, two part study of GSK3359609 in combination with tremelimumab in participants with selected, advanced solid tumors (2019) (1)
Correction to: Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer (2019) (1)
Survival of chemotherapy (chemo) refractory gastric or gastroesophageal junction cancer (GC/GEJC) patients from Flatiron Health (FH): Matched clinical characteristics to ATTRACTION-2 and CHECKMATE-032. (2018) (1)
Erratum to: Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma (2017) (1)
Immune-related tumor response dynamics as a marker for survival and treatment benefit during PD-1 inhibitor therapy. (2016) (1)
511 Initial results of a phase 1 study of intratumoral ONCR-177, an oncolytic herpes-simplex virus-1 expressing five immunomodulatory transgenes, in subjects with advanced injectable tumors (2021) (1)
Thromboembolism (TE) and association with survival in patients (pts) with melanoma receiving chemo– or immunotherapy. (2022) (1)
Abstract PS4-25: Comprehensive genomic analysis reveals molecular correlates of response to immune checkpoint inhibitors (ICI) in metastatic triple-negative breast cancer (mTNBC) (2021) (0)
Impact of Palliative Radiation on Lymphocyte Count and Neutrophil-to-Lymphocyte Ratio in Patients Receiving PD-1 Inhibitors (2018) (0)
The part of direct angiography as specification for an excision of giant recurrent tumor of retroperitoneal space (2013) (0)
Radiation and Immune Checkpoint Inhibitor Therapy in Mucosal Melanoma (2020) (0)
Erratum to: Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma (2017) (0)
Cell metastasis in Melanoma (2012) (0)
Immunotherapy: An Old and New Modality for the Treatment of Cancer. (2019) (0)
Clinical experience and correlates of ipilimumab 3 mg/kg with GM-CSF in advanced melanoma. (2015) (0)
Neoantigen-directed therapeutics in the clinic: where are we? (2023) (0)
A novel framework for evaluating biomarker response relationships in immuno-oncology (IO). (2018) (0)
Ipilimumab in Melanoma With Limited Brain Metastasis Treated With Stereotactic Radiosurgery (2012) (0)
Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors (2019) (0)
Correlation of shedding cryptic epitope (HU177) levels and treatment response in sera of melanoma patients (2008) (0)
Abstract A194: PEGylated human IL-10 (AM0010) in advanced solid tumors (2015) (0)
Multidisciplinary team management for high grade immune-related adverse events (irAEs): A single center experience. (2020) (0)
Immune-checkpoint blockade in cancer immunotherapy (2014) (0)
Characterization of the genetics of mucosal melanoma in patients treated with immunotherapy. (2019) (0)
Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma (2017) (0)
Topical imiquimod and cryotherapy in combination with systemic immunotherapy in unresectable stage IIIC melanoma (2022) (0)
Multicenter phase I/II trial of encorafenib with and without binimetinib in combination with nivolumab and low-dose ipilimumab in metastatic BRAF-mutant melanoma. (2021) (0)
Resistance mechanisms to PD-1 inhibition in melanoma (2016) (0)
Abstract 2846: Stereotypic patterns and genomic correlates of organotropism in metastatic melanoma (2021) (0)
Abstract CT098: Anti-tumor activity of PEGylated human IL-10 (AM0010) in patients with advanced solid tumors (2016) (0)
Topical imiquimod in combination with brachytherapy for unresectable cutaneous melanoma scalp metastases (2022) (0)
ATIM-32. PERSONALIZED NEOANTIGEN-TARGETING VACCINE GENERATES ROBUST SYSTEMIC AND INTRATUMORAL T CELL RESPONSES IN GLIOBLASTOMA (GBM) PATIENTS (2018) (0)
Clonal dynamics of alloreactive T cells in kidney allograft rejection after anti-PD-1 therapy (2023) (0)
What is the outcome of receiving subsequent therapy among patients (pts) with advanced/metastatic (Adv/Met) gastric or gastroesophageal junction cancer (GC/GEJC)? Experience from electronic health records (EHR). (2018) (0)
A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibition. (2023) (0)
Oblimersen 1-hour IV infusion in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma. (2010) (0)
Highlights from the literature (2013) (0)
Abstract A082: Single-cell RNA-sequencing of metastatic melanoma identifies a cancer cell-intrinsic program associated with immune checkpoint inhibitor resistance (2019) (0)
PEGylated human IL-10 (AM0010) monotherapy in refractory metastatic colorectal cancer. (2017) (0)
Combination immunotherapy: a road map The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters (2017) (0)
Erratum to: Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge (2017) (0)
Abstract LB-147: Comprehensive immune and molecular analysis of two metastatic melanoma patients treated with a personal neoantigen vaccine, NEO-PV-01, in combination with anti-PD1: A case study (2018) (0)
Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas (2015) (0)
Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy. (2023) (0)
Poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 VG in patients with melanoma. (2015) (0)
607 MCGRAW trial: evaluation of the safety and efficacy of an oral microbiome intervention (SER-401) in combination with nivolumab in first line metastatic melanoma patients (2022) (0)
3PDPEGylated human IL-10 (AM0010) in advanced solid tumors (2015) (0)
CLIN-MEDICAL + RADIATION THERAPIES (2012) (0)
Comprehensive analysis of five key immune related adverse events (irAE) from immune checkpoint blockers (ICB) CTLA-4 and PD-1 inhibitors in cancer patients. (2016) (0)
Automated Flow Synthesis of Tumor Neoantigen Peptides for Personalized Immunotherapy (2020) (0)
Capitalizing on the messenger: Intra-tumoral delivery of RNA with a systemic effect. (2021) (0)
Contents Vol. 81, 2011 (2012) (0)
Abstract PR02: A personalized neoantigen vaccine in patients with high risk melanoma (2016) (0)
Su1189 SAFETY OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH PREEXISTING INFLAMMATORY BOWEL DISEASE AND MICROSCOPIC COLITIS (2020) (0)
[Results of combined treatment with intraoperative radial therapy of soft tissue sarcoma]. (2013) (0)
Abstract A016: PEGylated IL-10 (pegilodecakin) induces systemic immune activation, CD8+ T-cell invigoration and polyclonal T-cell expansion in cancer patients (2019) (0)
[Long-term results of combined treatment of soft tissue sarcoma with the use of intraoperative radiotherapy]. (2013) (0)
1 A cloning and expression system to probe T cell receptor specificity and assess functional avidity to neoantigens Running Head : Defining T cell receptor specificity to neoantigen (2018) (0)
Abstract CT249: A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO) (2020) (0)
Abstract A99: Management of advanced melanoma: improved survival and barriers to access in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies (2020) (0)
Highlights from the literature (2019) (0)
Promising Experimental Therapies for Metastatic Melanoma (2011) (0)
Reply to F. Tomao et al. (2017) (0)
Immunotherapy in Cancer (2019) (0)
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial (2018) (0)
Analyses of PD-L1 and In ﬂ ammatory Gene Expression Association with Ef ﬁ cacy of Nivolumab (cid:1) Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer (2021) (0)
Phase I study with pegylated human IL-10 (AM0010) alone or in combination with anti-PD-1 or FOLFOX-immune biomarker update. (2017) (0)
Su1188 ABDOMINAL CT SHOULD NOT BE USED TO SCREEN FOR IMMUNE CHECKPOINT INHIBITOR COLITIS (2020) (0)
Issue information (2013) (0)
Cutaneous melanoma in the elderly: epidemiology and management (2010) (0)
A first-in-human study of pegylated recombinant human IL-10 (AM0010), daily administered for four months in selected advanced solid tumors. (2014) (0)
Treatment of Disseminated Melanoma (2011) (0)
P0110 Safety and anti-tumour activity of pegylated recombinant human IL-10 (AM0010) in selected advanced solid tumours (2015) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Patrick Alexander Ott?

Patrick Alexander Ott is affiliated with the following schools:

MD Anderson Cancer Center
University of Sydney
University of Louisville
New York University
Seoul National University

Patrick Alexander Ott's Academic­Influence.com Rankings

Why Is Patrick Alexander Ott Influential?

Patrick Alexander Ott's Published Works

Published Works

What Schools Are Affiliated With Patrick Alexander Ott?

Patrick Alexander Ott's AcademicInfluence.com Rankings